Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 93,610
  • Shares Outstanding, K 126,500
  • Annual Sales, $ 9,200 K
  • Annual Income, $ -29,370 K
  • 36-Month Beta 0.87
  • Price/Sales 10.45
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/14/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.71 +9.46%
on 07/24/17
0.84 -7.48%
on 06/30/17
-0.05 (-6.36%)
since 06/23/17
3-Month
0.71 +9.46%
on 07/24/17
1.02 -23.80%
on 04/26/17
-0.22 (-22.28%)
since 04/25/17
52-Week
0.26 +198.92%
on 12/13/16
1.51 -48.53%
on 03/14/17
+0.13 (+19.57%)
since 07/25/16

Most Recent Stories

More News
Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

If you want a Stock Review on RNN, PLX, NAVB, or BSTG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market, DailyStockTracker.com scans...

RNN : 2.35 (+2.17%)
NAVB : 0.47 (+4.44%)
BSTG : 0.49 (-3.92%)
PLX : 0.78 (+1.30%)
Breakfast Technical Briefing on Biotech Stocks -- Rexahn Pharma, Novavax, and Protalix BioTherapeutics

DailyStockTracker.com has issued research reports on the following four equities: Rexahn Pharmaceuticals Inc. (NYSEMKT: RNN), Novavax Inc. (NASDAQ: NVAX), and Protalix BioTherapeutics Inc. (NYSEMKT: PLX)....

RNN : 2.35 (+2.17%)
NVAX : 1.15 (-23.84%)
PLX : 0.78 (+1.30%)
Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock?

Investors in Protalix BioTherapeutics, Inc. (PLX) need to pay close attention to the stock based on moves in the options market lately.

PLX : 0.78 (+1.30%)
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.78 (+1.30%)
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease

Once Monthly Dosing Would Represent a 50% Reduction in Patient Infusions

PLX : 0.78 (+1.30%)
Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics

Stock-Callers.com has issued research reports on these following stocks: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Immunomedics Inc. (NASDAQ: IMMU), and...

PPHM : 4.54 (-2.58%)
RNN : 2.35 (+2.17%)
PLX : 0.78 (+1.30%)
IMMU : 8.72 (-2.13%)
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase(TM)) for the Treatment of Cystic Fibrosis

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive results from the Company's phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF). Sixteen...

PLX : 0.78 (+1.30%)
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?

Options traders are pricing in a big move for Protalix BioTherapeutics (PLX) shares as it has huge implied volatility

PLX : 0.78 (+1.30%)
Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight

NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or...

CERU : 0.66 (+4.76%)
PLX : 0.78 (+1.30%)
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.78 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Support & Resistance

2nd Resistance Point 0.82
1st Resistance Point 0.80
Last Price 0.78
1st Support Level 0.73
2nd Support Level 0.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.